Boehringer Ingelheim has moved one of its top pipeline ... Boehringer is a well-established presence in the IPF treatment market with Ofev (nintedanib), one of the German drugmaker's top-selling ...

Boehringer did not carry out a dedicated clinical trial to show the benefit of Ofev in this less severely affected population, but provided subgroup analyses from two earlier studies – INPULSIS ...

Boehringer Ingelheim is seeking regulatory approval ... Its tyrosine kinase inhibitor (TKI) Ofev (nintedanib) was approved by ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

Boehringer Ingelheim and Kyowa Kirin Co., Ltd. announced ... the treatment of pulmonary fibrosis with the introduction of Ofev, approved for the treatment of idiopathic pulmonary fibrosis (IPF ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...

A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...